Tlr-4 Rs4986790 Polymorphism Contributes To Cancer Risk: An Updated Meta-Analysis

The association of toll-like receptor 4 (TLR4) gene Asp299Gly (+896A/G, rs4986790) polymorphism with cancer risk, many studies have been revealed. However, the result is still uncertain. We carried out an updated meta-analysis of 44 studies that contained 13667 cases and 17115 controls to verify the degree of association. Evaluating the degree of association was using Odds ratio (OR) and 95% confidence intervals (95% CI). In total, we found a distinct increased risk of cancer susceptibility when all qualified studies were collected (G versus A: OR=1.115, 95% CI: 1.039-1.197, P=0.002; GG+AG versus AA: OR=1.125, 95% CI: 1.044-1.212, P=0.002; AG versus AA: OR=1.126, 95% CI: 1.044-1.215, P=0.002). Sub-group analysis suggested that TLR4 rs4986790 was associated with an increased risk of gastric cancer (G versus A: OR=1.587, 95% CI: 1.332-1.905, P=0.000; GG+AG versus AA: OR=1.625, 95% CI: 1.343-1.966, P=0.000; AG versus AA: OR=1.615, 95% CI: 1.332-1.958, P=0.000) and colorectal cancer (CRC) (G vs A: OR=1.238, 95% CI: 1.035-1.481, P=0.020; GG+AG versus AA: OR=1.217, 95% CI: 1.004-1.475, P=0.046). However, there were not enough evidence and data to assess the association of Asp299Gly between TLR4 gene and other cancers risk. The results of this meta-analysis indicated that TLR-4 Asp299Gly Polymorphism was correlated with an increased risk of cancer, particularly, gastric cancer and colorectal cancer (CRC).